Performance History
| Key Stats | |
|---|---|
| Open | $147.14 |
| Prev. Close | $147.39 |
| EPS | -2.64 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $18.64B |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 144.73 | 151.45 |
| 52 Week Range | 141.98 | 218.88 |
| Ratios | |
|---|---|
| P/B Ratio | 142.92 |
| Revenue | $1.82B |
| Operating M. % | -8.79% |
| Earnings | $0.00 |
| Earnings Growth % | 61.08% |
| EBITDA Margin % | -6.69% |
| ROE % | -1,500.66% |
| EPS | -2.64 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Alnylam Pharmaceuticals (ALNY)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB
- Headquarters
- Cambridge
- Employees
- 2002
- Exchange
- NASDAQ
Keep an eye on Alnylam Pharmaceuticals
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is the market capitalization of Alnylam Pharmaceuticals (ALNY)?
Alnylam Pharmaceuticals (ALNY) has a market capitalization of $18.96B. The average daily trading volume is 430.05K, indicating the stock's liquidity and investor engagement.
What is Alnylam Pharmaceuticals 's (ALNY) price per share?
The current price per share for Alnylam Pharmaceuticals (ALNY) is $147.76. The stock has seen a price change of $0.36 recently, indicating a 0.24% change. This reflects the stock's recent market performance and investor sentiment.
What is the 52-week high and low for Alnylam Pharmaceuticals (ALNY)?
For Alnylam Pharmaceuticals (ALNY), the 52-week high is $218.88, which is 48.13% from the current price. The 52-week low is $141.98, the current price is 4.07% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
Is Alnylam Pharmaceuticals (ALNY) a growth stock?
Alnylam Pharmaceuticals (ALNY) has shown an average price growth of 0.41% over the past three years. It has received a score of 60 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Alnylam Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
What is Alnylam Pharmaceuticals (ALNY) stock price performance year to date (YTD)?
As of the latest data, Alnylam Pharmaceuticals (ALNY) has a year-to-date price change of -24.2%. Over the past month, the stock has experienced a price change of 0.04%. Over the last three months, the change has been 0.22%. Over the past six months, the figure is -13.62%. Looking at a longer horizon, the five-year price change stands at 117.07%.
Is Alnylam Pharmaceuticals (ALNY) a profitable company?
Alnylam Pharmaceuticals (ALNY) has a net income of -$440.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 83.02% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -8.79% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.83B, with a revenue growth rate of 76.23%, providing insight into the company's sales performance and growth. The gross profit is $1.52B. Operating income is noted at -$282.18M. Furthermore, the EBITDA is -$122.3M.
News
Five Best-Performing Healthcare Companies Added Over $14 Billion to Their Stock Values Year-to-Date
Apple’s iPad Accounted for Nearly 2 in Every 5 Tablets Shipped Globally in 2023
Boeing’s Aircraft Deliveries to North America Hit 22-Year High at 293 Units
NYCB to Boost Capital and Liquidity Through $5 Billion Loan Sale to JPMorgan Chase
Gemini Ultra Training Costs in 2023 Neared $200 Million, More Than 2X GPT4
Microsoft Leads in Carbon Dioxide Removal (CDR) Credit Purchases, Acquiring 6.6M Tonnes, Surpassing All Other Buyers Combined
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.